

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1649JXM

**PASSWORD :**

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Feb 2 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 Expanded CAplus Coverage of US, Japanese, WIPO, EPO, and German patents  
NEWS 3 Feb 1 Addition of Machine-Translated Abstracts to CAplus  
NEWS 4 Feb 28 Patent Information Now Searchable in CAOLD  
NEWS 5 Mar 20 INPADOC: PRODUCER WARNING ABOUT DATA DELAYS  
NEWS 6 Mar 22 NEW FEATURES IN INPADOC - RANGE SEARCHING AND NEW SDI/UPDATE SEARCH FIELD  
NEWS 7 May 1 Beilstein Abstracts on STN - FILE BABS  
NEWS 8 May 1 RN CROSSOVER AND ANSWER SIZE LIMITS INCREASED  
NEWS 9 May 1 AIDSLINE has been reloaded  
NEWS 10 May 1 Searching Y2-K compliant Patent Numbers  
NEWS 11 May 9 Sequence Similarity Batch Search in DGENE  
NEWS 12 May 19 Weekly Statistics for New Entries now available in INPADOC  
NEWS 13 May 22 CITED REFERENCES NOW AVAILABLE IN CAPLUS AND CA FILE  
NEWS 14 May 22 POSTPROCESSING OF SEARCH RESULTS MAY BE AFFECTED BY ADDITION OF CITED REFERENCES TO CAPLUS, CA, REGISTRY, CASREACT, MARPAT, and MARPATPREV  
NEWS 15 Jun 2 KOREAN PATENTS NOW IN CAS DATABASES  
NEWS 16 Jun 20 WIPO/PCT Patents Fulltext Database now on STN

NEWS EXPRESS FREE UPGRADE 5.0C NOW AVAILABLE  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:28:51 ON 22 JUN 2000

=> file medline biosis embase caplus

**COST IN U.S. DOLLARS**

SINCE FILE  
ENTRY

**TOTAL  
SESSION**

FULL ESTIMATED COST 0.42 0.42

FILE 'MEDLINE' ENTERED AT 15:29:52 ON 22 JUN 2000

FILE 'BIOSIS' ENTERED AT 15:29:52 ON 22 JUN 2000  
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 15:29:52 ON 22 JUN 2000  
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:29:52 ON 22 JUN 2000  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s trre (s) polypeptide

L1 0 TRRE (S) POLYPEPTIDE

=> s trre (s) protein

L2 0 TRRE (S) PROTEIN

=> s trre

L3 9 TRRE

=> dup rem 13

PROCESSING COMPLETED FOR L3

L4 6 DUP REM L3 (3 DUPLICATES REMOVED)

=> d 14 ibib kwic

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2000 ACS  
ACCESSION NUMBER: 1999:736749 CAPLUS  
DOCUMENT NUMBER: 132:2794  
TITLE: Modulators affecting tumor necrosis factor  
receptor-releasing enzyme activity  
INVENTOR(S): Gatanaga, Tetsuya; Granger, Gale A.  
PATENT ASSIGNEE(S): The Regents of the University of California, USA  
SOURCE: PCT Int. Appl., 106 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958559	A2	19991118	WO 1999-US10793	19990514
WO 9958559	A3	20000120		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,			

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
PRIORITY APPLN. INFO.: US 1998-81385 19980514  
AB The biol. effects of the cytokine tumor necrosis factor (TNF) are mediated by binding to receptors on the surface of cells. Nine new proteins and polynucleotides are provided that promote enzymic cleavage and release of TNF receptors. The isolated polynucleotides have the following properties: (a) the sequence is expressed at the mRNA level in Jurkat T cells; (b) when COS-1 cells expressing TNF-receptor are genetically transformed to express the sequence, the cells have increased enzymic activity for cleaving and releasing the receptor. Also provided are screening methods for identifying addnl. compds. that influence TNF receptor shedding. TRRE activity alleviates septic shock and decreases tumor necrotizing activity, and the modulator expression products are effective in treating septic shock. As the active ingredient in a pharmaceutical compn., the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathol. of disease.

=> file medline biosis embase caplus uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.87	12.29
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.56	-0.56

FILE 'MEDLINE' ENTERED AT 15:32:44 ON 22 JUN 2000

FILE 'BIOSIS' ENTERED AT 15:32:44 ON 22 JUN 2000  
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 15:32:44 ON 22 JUN 2000  
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:32:44 ON 22 JUN 2000  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:32:44 ON 22 JUN 2000  
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s trre

L5 11 TRRE

=> dup rem 15

PROCESSING COMPLETED FOR L5  
L6 8 DUP REM L5 (3 DUPLICATES REMOVED)

=> d 16 ibib kwic total

L6 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2000 ACS  
ACCESSION NUMBER: 1999:736749 CAPLUS

DOCUMENT NUMBER: 132:2794  
TITLE: Modulators affecting tumor necrosis factor receptor-releasing enzyme activity  
INVENTOR(S): Gatanaga, Tetsuya; Granger, Gale A.  
PATENT ASSIGNEE(S): The Regents of the University of California, USA  
SOURCE: PCT Int. Appl., 106 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958559	A2	19991118	WO 1999-US10793	19990514
WO 9958559	A3	20000120		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1998-81385 19980514

AB The biol. effects of the cytokine tumor necrosis factor (TNF) are mediated

by binding to receptors on the surface of cells. Nine new proteins and polynucleotides are provided that promote enzymic cleavage and release of TNF receptors. The isolated polynucleotides have the following properties: (a) the sequence is expressed at the mRNA level in Jurkat T cells; (b) when COS-1 cells expressing TNF-receptor are genetically transformed to express the sequence, the cells have increased enzymic activity for cleaving and releasing the receptor. Also provided are screening methods for identifying addnl. compds. that influence TNF receptor shedding. TRRE activity alleviates septic shock and decreases tumor necrotizing activity, and the modulator expression products are effective in treating septic shock. As the active ingredient

in a pharmaceutical compn., the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathol. of disease.

L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2000 ACS  
ACCESSION NUMBER: 1998:324897 CAPLUS  
DOCUMENT NUMBER: 129:13976  
TITLE: Isolated tumor necrosis factor receptor releasing enzyme and pharmaceutical compositions comprising the enzyme  
INVENTOR(S): Granger, Gale A.; Gatanaga, Tetsuya  
PATENT ASSIGNEE(S): Regents of the University of California, USA;  
Granger,  
SOURCE: Gale A.; Gatanaga, Tetsuya  
PCT Int. Appl., 109 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9820140	A1	19980514	WO 1997-US19930	19971105
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9851621	A1	19980529	AU 1998-51621	19971105
EP 938548	A1	19990901	EP 1997-946457	19971105
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
NO 9902187	A	19990701	NO 1999-2187	19990505
PRIORITY APPLN. INFO.:			US 1996-30761	19961106
			WO 1997-US19930	19971105

AB A human tumor necrosis factor receptor releasing enzyme (TRRE) is prep'd. from a cultured human cell line THP-1 (human monocytic leukemia)

stimulated with PMA and characterized. The native form of TRRE exhibits a mol. wt. of 120 kDa on SDS-PAGE. Its enzyme activity is sensitive to metalloprotease inhibitor, but not to serine or cysteine protease inhibitor. A compn. contg. TRRE for treating a disease assoc'd. with altered levels of tumor necrosis factor is also described. Also claimed are methods of (1) diagnosing and treating cancer or inflammation assoc'd. with TNF and (2) administration of pharmaceutical compns. contg. TNF. Preferably, the TRRE activity is regulated local to the site of the condition to be treated. In the case of diseases

assoc'd. with elevated levels of TNF, such as rheumatoid arthritis, TRRE is administered to the site of inflammation in an amt. sufficient to decrease the local levels of TNF. In the case of diseases, such as cancer, that benefit from increased levels of TNF, the level of TRRE is decreased at the disease site.

L6 ANSWER 3 OF 8 BIOSIS COPYRIGHT 2000 BIOSIS  
 ACCESSION NUMBER: 1996:257458 BIOSIS  
 DOCUMENT NUMBER: PREV199698813587  
 TITLE: Identification and characterization of soluble TNF

receptor

releasing enzyme (TRRE) from PMA-stimulated human monocytic THP-1 cells.

AUTHOR(S): Katsura, K. (1); Park, M. (1); Gatanaga, M. (1);  
 Takishima,

K.; Granger, G. A. (1); Gatanaga, T. (1)

CORPORATE SOURCE: (1) Univ. Calif., Irvine, CA USA

SOURCE: Proceedings of the American Association for Cancer Research

Annual Meeting, (1996) Vol. 37, No. 0, pp. 492.  
 Meeting Info.: 87th Annual Meeting of the American Association for Cancer Research Washington, D.C., USA

April

20-24, 1996

ISSN: 0197-016X.

DOCUMENT TYPE: Conference

LANGUAGE: English

TI Identification and characterization of soluble TNF receptor releasing enzyme (TRRE) from PMA-stimulated human monocytic THP-1 cells.

L6 ANSWER 4 OF 8 MEDLINE DUPLICATE 1  
ACCESSION NUMBER: 96222497 MEDLINE  
DOCUMENT NUMBER: 96222497  
TITLE: Identification of the proteolytic enzyme which cleaves human p75 TNF receptor in vitro.  
AUTHOR: Katsura K; Park M; Gatanaga M; Yu E C; Takishima K; Granger G A; Gatanaga T  
CORPORATE SOURCE: Department of Molecular Biology and Biochemistry, University of California, Irvine 92717-3900, USA.  
SOURCE: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1996 May 15) 222 (2) 298-302.  
Journal code: 9Y8. ISSN: 0006-291X.  
PUB. COUNTRY: United States  
LANGUAGE: Journal; Article; (JOURNAL ARTICLE)  
FILE SEGMENT: English Priority Journals; Cancer Journals  
ENTRY MONTH: 199610  
AB . . . fragments, respectively. In this study, the enzymatic activity involved in the cleavage of human p75 TNF-R, named TNF-R releasing enzyme (TRRE), was identified in the culture supernatant of PMA-stimulated THP-1 cells using an activity assay system established by our group. When THP-1 cells were stimulated with PMA, TRRE was released rapidly into the supernatant, reaching maximal activity within 3 hours. The release of TRRE into the culture supernatant depended on the concentration of PMA and FCS. TRRE activity was partially inhibited by chelating agents, suggesting that TRRE may be a metallo-protease-like enzyme. This is the first successful attempt to establish a stable TRRE source with a reliable assay system.

L6 ANSWER 5 OF 8 USPATFULL  
ACCESSION NUMBER: 93:83356 USPATFULL  
TITLE: Facsimile apparatus comprising means for continuously transmitting plural groups of image data to the same receiver party  
INVENTOR(S): Hamano, Hiroaki, Osaka, Japan  
Nakajima, Akio, Toyokawa, Japan  
PATENT ASSIGNEE(S): Minolta Camera Kabushiki Kaisha, Osaka, Japan  
(non-U.S.  
corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5251043	19931005
APPLICATION INFO.:	US 1991-776636	19911015 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1990-277402	19901015
	JP 1990-277403	19901015
	JP 1990-277404	19901015

DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Coles, Sr., Edward L.  
ASSISTANT EXAMINER: Rogers, Scott A.  
LEGAL REPRESENTATIVE: Willian Brinks Olds Hofer Gilson & Lione  
NUMBER OF CLAIMS: 13  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 31 Drawing Page(s)  
LINE COUNT: 1632

DETD . . . key 52 is referred to as a TR key, and the transmission reservation key 57 is referred to as a **TRRE** key.

L6 ANSWER 6 OF 8 BIOSIS COPYRIGHT 2000 BIOSIS  
ACCESSION NUMBER: 1993:227104 BIOSIS  
DOCUMENT NUMBER: PREV199395118279  
TITLE: Do birch trees (*Betula pendula*) grow better if foraged by wood ants.  
AUTHOR(S): Mahdi, T.; Whittaker, J. B.  
CORPORATE SOURCE: Biological Sci. Div., Inst. Environmental and Biological Sci., Univ. Lancaster, Lancaster LA1 4YQ UK  
SOURCE: Journal of Animal Ecology, (1993) Vol. 62, No. 1, pp. 101-116.  
ISSN: 0021-8790.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
AB. . . of the insect herbivore community on *Betula pendula* is markedly changed by *F. rufa* predation, the effect of this on **tre** growth is slight.

L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2000 ACS  
ACCESSION NUMBER: 1985:1908 CAPLUS  
DOCUMENT NUMBER: 102:1908  
TITLE: The tolerance of tree lucerne to some soil-applied herbicide  
AUTHOR(S): Hurrell, G. A.; Bourdot, G. W.  
CORPORATE SOURCE: Agric. Res. Div., MAF, Lincoln, N. Z.  
SOURCE: Proc. N. Z. Weed Pest Control Conf. (1984), 37th, 210-12  
CODEN: PZWPAL; ISSN: 0370-2804  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT Plant growth and development  
(by **tre** lucerne, soil-applied herbicides effect on)

L6 ANSWER 8 OF 8 USPATFULL  
ACCESSION NUMBER: 78:39684 USPATFULL  
TITLE: Method for data transmission and a system for carrying out the method  
INVENTOR(S): Westman, Kjell Harry, Vallingsby, Sweden  
PATENT ASSIGNEE(S): U.S. Philips Corporation, New York, NY, United States  
(U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4103288	19780725
APPLICATION INFO.:	US 1976-723155	19760914 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1975-10432	19750918
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Pitts, Harold I.	
LEGAL REPRESENTATIVE:	Trifari, Frank R.; Biren, Steven R.	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1087	

DETD . . . and input of which are connected to a central station 1 via a belonging modem M1 and a transmission/reception circuit **TRRE**, respectively. To the loop are connected four terminal stations 2, 3, 4, 5 via the belonging modems M2, M3, M4. . . .  
DETD In FIG. 5 is disclosed an embodiment of the transmission/reception

circuit **TRRE**, through which the central station 1 (TC) (FIG. 1) is connected to the series transmission loop. The horizontal line at.

DETDX . . . figure represents the border line with respect to the central station 1 with the signals shown which are interchanged between **TRRE** and TC. The horizontal line at the bottom of the figure represents the border line with respect to the transmission. . . .  
DETDX **TRRE** is composed of a central control unit CO, in which is comprised control circuits of a type well known by. . . .  
DETDX On the input side **TRRE** comprises a central control unit CO to be described in more detail with reference to FIG. 7 and is furthermore.

DETDX . . . diagram of the DT, DTI respectively, circuit comprised in the connection circuit (FIG. 4) of each terminal and in the **TRRE** circuit of the central station (FIG. 5).

DETDX The central control unit CO (FIG. 5) of **TRRE** is disclosed in FIG. 7. CO is composed of a 4 bit counter COUNT4 which may be controlled

so as. . . .

DETDX . . . and DT in all terminal stations, which are thereby brought into synchronism. The SYN characters are received in IDBR of **TRRE** after having circulated the loop and are decoded in DTI, which will then activate its SYN output, which will in. . . .

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.99	27.28
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.11	-1.67

STN INTERNATIONAL LOGOFF AT 15:33:26 ON 22 JUN 2000

09200 35Y

09700354 Results

SEQ ID NO: 9

RESULT 10

G22793/c

LOCUS G22793 405 bp DNA STS 31-MAY-1996

DEFINITION human STS WI-11758, sequence tagged site.

ACCESSION G22793

VERSION G22793.1 GI:1343119

KEYWORDS STS; STS sequence; primer; sequence tagged site.

SOURCE human STSs derived from sequences in dbEST and the Unigene collection.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 405)

AUTHORS Hudson, T.

TITLE Whitehead Institute/MIT Center for Genome Research; Physically Mapped STSs

JOURNAL Unpublished (1995)

COMMENT

Contact: Thomas Hudson

Whitehead Institute/MIT Center for Genome Research

Whitehead Institute for Biomedical Research

9 Cambridge Center, Cambridge MA 02142 USA

Tel: 617 252 1900

Fax: 617 252 1902

Email: thudson@genome.wi.mit.edu

Primer A: TTTTCCTCTTTTATTAAGTCGGC

Primer B: TGATGGTGATCTGGCACTC

STS size: 127

PCR Profile:

Presoak:

Denaturation:

Annealing: 56 degrees C

Polymerization:

PCR Cycles: 35

Thermal Cycler:

Protocol:

Template: 10 ng

Primer: each 5 pM

dNTPs: each 4 nM

Taq Polymerase: 0.025 units/ul

Total Vol: 20 ul

Buffer:

MgCl2: 1.5 mM

KCl: 50 mM

Tris-HCL: 10 mM

pH: 9.3

Derived from dbEST (genbank accession R12670).

FEATURES Location/Qualifiers

source	1. .405
	/organism="Homo sapiens"
	/db_xref="taxon:9606"
	/map="355.3 cR from top of Chr17 linkage group"
STS	14. .140
primer_bind	14. .37
primer_bind	complement(121. .140)

BASE COUNT 92 a 107 c 100 g 100 t 6 others

ORIGIN

Query Match 27.9%; Score 330.6; DB 54; Length 405;

Best Local Similarity 96.7%; Pred. No. 1.8e-69;

Matches 356; Conservative 0; Mismatches 9; Indels 3; Gaps 2;

Qy 756 CTGGAGCCTAAGCTGGACC--TGCTACTGGAGAAGACCAAGGAGCTGCAGAAGCTGATTG 813  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 400 CTGGAGCCTAAGCTGGACCCCTGCCTACTGGANAAGCCCAAGGAGCTGCAGAAGCTGANTG 341  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Qy 814 AAGCTGA-CATCTCCAAGAGGTACAGCGGGCGCCCTGTGAACCTGATGGAACCTCTCTG 872  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 340 AAGCTGACCATCTCCAANAGGTACAGCGGGCGCCCTGTGAACCTGATGGAACCTCTCTG 281  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Qy 873 TGACACCCCTCCGTGTTCTGCCTGCCATCTTCCTCGCTTTGGGATGAAGATGATAGCC 932  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 280 TGANACCCCTCCGTGNTCTTGCTGCCATCTTCCTCGCTTTGGGATGAAGATGATAGCC 221  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Qy 933 AGGGCTGTTGTTTGGGCCCTCAAGGCAAAAGACCAGGCTGACTGGAAGATGGAAAGC 992  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 220 AGGGCTGTTGTTTGGGCCCTCAAGGCAAAAGACCAGGCTGACTGGAAGATGGAAAGC 161  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Qy 993 CACAGGAAGGAAGCGGCACCTGATGGTATCTGGCACTCTCCATGTTCTACAGAAAG 1052  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 160 CACAGGAAGGAAGCGGCACCTGATGGTATCTGGCACTCTCCATGTTCTACAGAAAG 101  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Qy 1053 CTGTGGTATTGGCCCTGTGGTCTATCAGGCAAAACCACAGATTCTCCTTAGTTAGT 1112  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 100 CTGTGGTATTGGCCCTGTGGTCTATCAGGCAAAACCACAGATTCTCCTTAGTTAGT 41  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Qy 1113 ATAGCGCA 1120  
 ||||| |  
 Db 40 ATAGCGGA 33

RESULT 1  
 AAZ38861  
 ID AAZ38861 standard; DNA; 1187 BP.  
 XX  
 AC AAZ38861;  
 XX  
 DT 17-FEB-2000 (first entry)  
 XX  
 DE Human Jurkat cell clone P2-14 AIM9 which affects TRRE activity.  
 XX  
 KW Human; Jurkat cell; tumour necrosis factor receptor releasing enzyme;  
 KW TRRE; cytokine; TNF; identification; cytostatic; anti-inflammatory;  
 KW cardiant; immunomodulator; antiarthritic; antibacterial; cancer;  
 KW heart failure; cachexia; inflammation; endotoxic shock; arthritis;  
 KW multiple sclerosis; sepsis; ds.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO9958559-A2.  
 XX  
 PD 18-NOV-1999.  
 XX  
 PF 14-MAY-1999; 99WO-US10793.  
 XX  
 PR 14-MAY-1998; 98US-0081385.  
 XX  
 PA (REGC ) UNIV CALIFORNIA.  
 XX  
 PI Gatanaga T, Granger GA;  
 XX  
 DR WPI; 2000-039067/03.  
 XX  
 PT Tumor necrosis factor receptor releasing enzyme modulators and  
 PT polynucleotides -  
 XX  
 PS Claim 2; Page 68; 106pp; English.  
 XX  
 CC The present invention describes isolated polynucleotides (A) comprising a  
 CC sequence expressed at the mRNA level in Jurkat T cells and showing  
 CC increased enzymatic activity for cleaving and releasing the tumour  
 CC necrosis factor (TNF) receptor in genetically modified COS-1 cells

CC expressing the receptor. The present sequence represents a specifically  
CC claimed clone which affects tumour necrosis factor receptor releasing  
CC enzyme (TRRE) activity. Methods from the present invention can be used to  
CC assess a disease condition associated with altered TRRE activity. The  
CC polypeptides, polynucleotides and antibodies can be used to decrease or  
CC increase signal transduction from a cytokine in a cell. The polypeptides,  
CC polynucleotides and antibodies may be used to treat heart failure,  
CC cachexia, inflammation, endotoxic shock, arthritis, multiple sclerosis  
CC and sepsis, and cancer.

XX

SQ Sequence 1187 BP; 278 A; 288 C; 369 G; 252 T; 0 other;

Query Match 100.0%; Score 1187; DB 21; Length 1187;  
Best Local Similarity 100.0%; Pred. No. 5.4e-281;  
Matches 1187; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GAGCTCGCGCCTGCAGGTCGACACTAGTGGATCCAAAGAATTGGCAGGAGGGAACT 60  
Db 1 gagctcgccgcctgcaggctcgacactagtggatccaaagaattggcagcaggaaact 60

Qy 61 CAACGGGTACGAGTGGAGGACAGGGACAGAGCCCTCTGTGGTGGAACGACCCACCTCG 120  
Db 61 caacgggtacgactggaggacaggacaggccctctgtggtaacgacccacctcg 120

Qy 121 AGGAGCTCCTGAGCAGGTGGCAGAAGATGCGATTGACTGGGCGACTTGGGTAGAGG 180  
Db 121 aggagttcctgagcagggtggcagaagatgcgattgactggggactttggggtagagg 180

Qy 181 CAGTGTCTGAGGGGACTGACTCTGGCATCTGCCAGGGCTGGAAATCGACTGGGCA 240  
Db 181 cagtgtctgaggggactgactctggcatctggcaggctgctggaaatcgactgggca 240

Qy 241 TCTTCCCGGAATCAGATTCAAAGGATCCTGGAGGTGATGGGATAGACTGGGAGACGATG 300  
Db 241 tcttcccgaaatcagattcaaaggatcctggagggtgatgggatagactgggagacgatg 300

Qy 301 CTGTTGCTTGAGATCACAGTGTGGAAAGCAGGAACCCAGGCTCCAGAAGGTGTTGCCA 360  
Db 301 ctgttgcttgagatcacagtgtggaaagcaggaaacccaggctccagaagggtgttgc 360

Qy 361 GGGGCCAGATGCCCTGACACTGCTTGAATACACTGAGACCCCGAATCAGTCCTGATG 420  
Db 361 ggggcccagatgccctgacactgcttgaatacactgagaccccgaaatcagttccttgatg 420

Qy 421 AGCTCATGGAGCTTGAGATCTTCTAGGCCAGAGAGCAGTGGAGTTGAGTGAGGAGGCAG 480  
Db 421 agctcatggagcttgagatcttcttagcccgaggcgtggagttgagtggaggaggcag 480

Qy 481 ATGTCCTGCTGTGAGCCAGTCCAGCTGGCTCAGCCATCTGCAGGGCCAGACCAAAG 540  
Db 481 atgcctctgtgtgagccagttccagctggctcagccatctgcagggccagaccaaag 540

Qy 541 AGAAGATGGTTACCATGGTGTAGTGTGGAGGATCTGATTGGCAAGCTTACCACTTC 600  
Db 541 agaagatggttaccatggtgtcagtgtggaggatctgtggcaagcttaccagtcttc 600

Qy 601 AGCTGCAACACCTGTTATGATCCTGGCTCACCAAGGTATGTGGACCGAGTGACTGAAT 660  
Db 601 agctgcaacacctgtttatgatcctggctcaccaaggatgtggaccgagtgactgaat 660

Qy 661 TCCTCCAGCAAAAGCTGAAGCAGTCCCAGCTGCTGGCTTGAAGAAAGAGCTGATGGTGC 720  
Db 661 tcctccagcaaaagctgaagcagtcctccagctgtggcttgaagaaagagctgtggtg 720

Qy 721 AGAACGAGCAGGAGGCACCTTGAGGAGCAGGCGGCTCTGGAGCCTAAGCTGGACCTGCTAC 780  
Db 721 agaagcagcaggaggacttgaggagcaggcggctctggagcctaagctggacctgctac 780

Qy 781 TGGAGAAAGACCAAGGAGCTGCAGAACCTGATTGAAGCTGACATCTCCAAGAGGTACAGCG 840  
Db 781 tggagaaagaccaaggacttgaggagcaggcggctctggagcctaagctggacctgctac 840

Db 781 tggagaagaccaaggagctgcagaagctgattgaagctgacatctccaagaggtacagcg 840  
Qy 841 GGCGCCCTGTGAACCTGATGGGAACCTCTCTGTGACACCCCTCGTGTCTGCCTGCCA 900  
|||  
Db 841 ggcgcctgtgaacctgatggaaacctctctgtgacaccctccgtttcgtccca 900  
Qy 901 TCTTCTCGCTTGGGATGAAGATGATGCCAGGGCTGTTGGGCCCTCAAGG 960  
|||  
Db 901 tcttctccgctttggatgaagatgatgccaggctgtgtttggccctcaagg 960  
Qy 961 CAAAAGACCAGGCTGACTGAAAGATGAAAGCCACAGGAAGGAAGCGGCACCTGATGGTG 1020  
|||  
Db 961 caaaagaccaggctgactgaaagatggaaagccacaggaaggaaagcggcacctgtgg 1020  
Qy 1021 ATCTTGGCACTCTCCATGTTCTCTACAAGAAGCTGTGGTGATTGGCCCTGTGGTCTATCA 1080  
|||  
Db 1021 atcttggcaactccatgttctctacaagaagctgtggatggccctgtggtctatca 1080  
Qy 1081 GGCAGAAAACCACAGATTCTCCTCTAGTTAGTATAGCGCAAAAGCTTCTCGAGAGTACT 1140  
|||  
Db 1081 ggcgaaaaccacagattcccttctagtttagtatacgcaaaaagctctcgagact 1140  
Qy 1141 TCTAGAGCGGCCGCGGGCCATCGATTTCCACCCGGGTGGGTACC 1187  
|||  
Db 1141 tctagagcggccgcggccatcgatttccaccgggtgggtacc 1187

RESULT 4  
AAX10455/c  
ID AAX10455 standard; DNA; 127 BP.  
XX  
AC AAX10455;  
XX  
DT 30-MAR-1999 (first entry)  
XX  
DE Human biallelic polymorphic DNA fragment WI-11758.  
XX  
KW Polymorphism; biallelic; human; forensic; paternity testing; disease;  
KW detection; phenotypic typing; characteristic; infection; hereditary;  
KW autoimmune disease; cancer; inflammation; drug; therapy; medicament;  
KW treatment; marker; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9820165-A2.  
XX  
PD 14-MAY-1998.  
XX  
PF 05-NOV-1997; 97WO-US20313.  
XX  
PR 06-NOV-1996; 96US-0030455.  
XX  
PA (WHED ) WHITEHEAD INST BIOMEDICAL RES.  
XX  
PI Hudson T, Lander ES, Wang D;  
XX  
DR WPI; 1998-286974/25.  
XX  
PT New isolated nucleic acid segments from the human genome - used for  
PT determining polymorphic forms for use in e.g. forensics, paternity  
PT testing or phenotypic typing for disease  
XX  
PS Claim 1; Page 52; 310pp; English.  
XX  
CC AAX10269-X12937 are human DNA fragments which contain biallelic  
CC polymorphic markers which have been isolated using the primers  
CC represented in AAX09121-X10268. The base occupying the polymorphic site  
CC is indicated by the appropriate IUPAC-IUB ambiguity code. These fragments  
CC can be used in methods for determining polymorphic forms in an individual  
CC for use in e.g. forensics, paternity testing or for phenotypic typing for  
CC diseases such as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan

CC syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease,  
CC familial hypercholesterolemia, polycystic kidney disease, hereditary  
CC spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary  
CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos  
CC syndrome, osteogenesis imperfecta, acute intermittent porphyria,  
CC autoimmune diseases, inflammation, cancer, diseases of the nervous  
CC system, infection by pathogenic microorganisms, and characteristics such  
CC as longevity, appearance (e.g. baldness, obesity), strength, speed,  
CC endurance, fertility, and susceptibility or receptivity to particular  
CC drugs or therapeutic treatments. The isolated polymorphic nucleic acid  
CC segments can also be used to produce medicaments for the treatment or  
CC prophylaxis of such diseases.

XX

SQ Sequence 127 BP; 35 A; 30 C; 25 G; 36 T; 1 other;

Query Match 8.9%; Score 106; DB 19; Length 127;  
Best Local Similarity 98.1%; Pred. No. 5.9e-17;  
Matches 106; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
Qy 1013 TGATGGTATCTGGCACTCTCCATGTTCTCTACAAGAAGCTGGTGATTGGCCCTGTG 1072  
Db 127 TGATGGTATCTGGCACTCTCCATGTTCTCTACAAGAAGCTGGTGATTGGCCCTGTG 68  
Qy 1073 GTCTATCAGGCAGAAACACAGATTCTCCTCTAGTTAGTATAGCGCA 1120  
Db 67 GTCTAYCAGGCAGAAACACAGATTCTCCTCTAGTTAGTATAGCGGA 20